Ferrous sulfate 325mg Absolute change from Gifford 2014 [] Placebo 6 weeks 24 Patients with adults baseline in taken orally once a hypoferremic anemia hemoglobin day. concentration attributed to ferrous sulfate, iron related hematologic parameters, anthopometrics, sputum iron, Pulmonary Exacerbation Score (PES), sputum microbiome. Engelen 2013 [] 6.7g high-leucine 6.7g balanced mixture 1 day 15 Clinically stable Range: 10-21 years Whole body protein EAA mixture of total (EAA and inpatients after and Arginine (containing 41% non-essential) amino antibiotic treatment metabolism, leucine) + 15g acids + 15g with no symptoms of anthropometrics, lung carbohydrates, orally carbohydrates, orally pulmonary function. or enterally. or enterally. exacerbation. Pancreatic insufficient. Alicandro 2013 [] 100 mg/ kg/day of Placebo 12 months 41 Clinically stable, Range: 6-10 years Percentage change in DHA during the first pancreatic plasma AA:DHA ratio, month and 1 g/day in insufficient, able to number of pulmonary the remaining 11 perform respiratory exacerbations months as placebo. function compared to the previous year, lung function, anthropometrics, body composition, serum TNF-a, IL8 and CRP, serum and retinol.
Gifford 2014 [] Ferrous sulfate 325mg taken orally once a day. Placebo 6 weeks 24 Patients with hypoferremic anemia adults Absolute change from baseline in hemoglobin concentration attributed to ferrous sulfate, iron related hematologic parameters, anthopometrics, sputum iron, Pulmonary Exacerbation Score (PES), sputum microbiome. Engelen 2013 [] 6.7g high-leucine EAA mixture (containing 41% leucine) + 15g carbohydrates, orally or enterally. 6.7g balanced mixture of total (EAA and non-essential) amino acids + 15g carbohydrates, orally or enterally. 1 day 15 Clinically stable inpatients after antibiotic treatment with no symptoms of pulmonary exacerbation. Pancreatic insufficient. Range: 10-21 years Whole body protein and Arginine metabolism, anthropometrics, lung function. Alicandro 2013 [] 100 mg/ kg/day of DHA during the first month and 1 g/day in the remaining 11 months as placebo. Placebo 12 months 41 Clinically stable, pancreatic insufficient, able to perform respiratory function Range: 6-10 years Percentage change in plasma AA:DHA ratio, number of pulmonary exacerbations compared to the previous year, lung function, anthropometrics, body composition, serum TNF-a, IL8 and CRP, serum and retinol.
MPG_2016_02_10_DAITCH_JPGN-15-367_SDC1.docx